No. 7 Medical Innovation for 2018: Arsenal of Targeted Breast Cancer Therapies (Video)
The new arsenal of targeted breast cancer therapies will be the No. 7 most influential medical innovation for 2018, predict experts at Cleveland Clinic.
In 2018, targeted therapies will be used more widely to treat breast cancer, a disease that kills more than 40,000 American women per year. A variety of new targeted treatments — such as PARP inhibitors for patients with specific BRCA1 or BRCA2 mutations, and novel CDK 4/6 inhibitors for ER-Positive/HER-2-negative breast cancer — are having positive outcomes in clinical trials.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
In addition, novel HER-2 targeted agents continue to show benefits in a subgroup of HER-2-positive patients.
Experts believe that the cumulative results of these studies point to an increasing survival rate, and perhaps the eventual end of chemotherapy for a significant number of breast cancer patients.
In this video, learn more about why targeted breast cancer therapies are one of Cleveland Clinic’s Top 10 Medical Innovations for 2018.